---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-006106"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:41:41.591683+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NextCure Q1 net loss narrows to $11.0M; LNCB74 ADC Phase 1 dosing cohort 3

## Summary
- Cash $55.9M as of March 31, 2025, down from $68.6M; expected runway into H2 2026.
- Net loss $11.0M vs $17.1M YoY; R&D expense $7.9M vs $11.4M YoY due to 2024 restructuring.
- LNCB74 (B7-H4 ADC) Phase 1 cleared cohort 2, dosing cohort 3; backfill cohorts planned H2 2025.
- Proof-of-concept data readout for LNCB74 planned in first half of 2026.
- Preclinical NC181 (Alzheimer's) and NC605 (osteogenesis imperfecta) seeking partners; IND filings possible in 12-18 months if funded.

## SEC filing metadata
- accession: 0001558370-25-006106
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837025006106/0001558370-25-006106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837025006106/nxtc-20250501x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-006106
- JSON: https://secwatch.observer/filing/0001558370-25-006106.json
- Plain text: https://secwatch.observer/filing/0001558370-25-006106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.